12:48 PM
 | 
Jun 29, 2018
 |  BioCentury  |  Finance

Carisma’s attraction

Why Wellington Partners picked Carisma for its first macrophage investment

Macrophage immunotherapy play Carisma Therapeutics Inc. has developed biomarkers that it can use to track macrophage activity and tumor response in preclinical and clinical studies, leading Wellington Partners to join its $53 million series A round.

AbbVie Ventures and HealthCap co-led the round, which closed on June 27, and were joined by fellow existing investors IP Group plc (LSE:IPO), Penn Medicine and Grazia Equity and additional new investors TPG Biotech, MRL Ventures Fund and Agent Capital.

Carisma spun out of the University...

Read the full 398 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >